Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases.
The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension.
It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
|CEO||Punit S. Dhillon B.A., BA|
11250 El Camino Real, Suite 100
San Diego, California 92130
|Fiscal Year||January - December|
|Punit S. Dhillon B.A., BA||Executive Chairman, President, Chief Executive Officer and Secretary|
|Kaitlyn Melanie Arsenault CPA||Chief Financial Officer|
|Dr. Christopher G. Twitty Ph.D.||Chief Scientific Officer|
|Tu Diep M.Sc.||Chief Development Officer|
Latest SEC Filings
|Nov 14, 2023||10-Q||Quarterly Report|
|Nov 7, 2023||8-K||Current Report|
|Oct 17, 2023||DEF 14C||Filing|
|Oct 3, 2023||8-K||Current Report|
|Oct 3, 2023||PRE 14C||Filing|
|Sep 7, 2023||8-K||Current Report|
|Sep 1, 2023||8-K/A||[Amend] Current report|
|Aug 29, 2023||D||Notice of Exempt Offering of Securities|
|Aug 28, 2023||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Aug 28, 2023||SC 13D||General statement of acquisition of beneficial ownership|